PATENT CLAIM ANALYSIS

Application Number: 16144198
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["514", "263100"]

Abstract:
The disclosure provides methods for treating cancer, including but not limited to, hematopoietic and lung cancers, using the HSP90 inhibitor, MPC-0767, as monotherapy and in combination therapy with additional active agents, including but not limited to, inhibitors of Bcl-2, EZH2 inhibitors, Ras/Raf/MEK/ERK pathway inhibitors, checkpoint inhibitors, DNMT inhibitors, ATO and chemotherapeutic agents. The disclosure also provides related compositions and methods of use.

Claim (Index 9):
The method of  claim 1 , wherein the cancer is selected from gastric cancer, colon cancer, prostate cancer, small-cell lung cancer, non-small cell lung cancer (NSCLC), ovarian cancer, lymphoma, acute myeloid leukemia (AML), acute promyelocytic leukemia, chronic lymphocytic leukemia (CLL), multiple myeloma, renal cell carcinoma, gastrointestinal stromal tumor, chronic myeloid leukemia, glioblastoma multiforme, astrocytomas, medulloblastomas, melanoma, breast cancer, and pancreatic cancer.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 97.0
- Lexical Diversity: 1.65217
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15419642', '15514043', '14671613', '14026778', '14447139']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7992033664269096
- 35 USC 102 Novelty (BERT): 0.5157980042378852
- Combined Prediction Score: 0.7708628302080072
- Mean Citation Score: 313.314552
- Max Citation Score: 320.49805
- Similarity Product: 276.2479580854237

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test